Have questions for our experts or want more information?
Contact Us Today
Webinar Overview: Strategies to Optimize Starting Material for Autologous and Allogeneic Cell Therapies
Leukopaks are a common source of cellular starting material in cell therapy development, but several challenges can hamper their utility, including donor availability, donor-to-donor variability, and supply chain issues (for fresh leukopaks).
This webinar is designed to help you put a plan together that not only ensures a consistent stream of starting material but also increases access to a recallable pool of donors. We’ll share real-world data that highlights white blood cell yields and immune cell frequencies in donor periods as little as two weeks and why cryopreserved leukopaks are beneficial for both autologous and allogeneic cell therapies.
By the end of this presentation, you’ll learn how:
- Utilizing recallable donors preserves consistency in leukopak collections
- Different donor referral periods affect cellular yield and characterizations in leukopaks
- Cryoperservation impacts leukopak stability
Webinar Presenter
Wassim Basheer, PhD
Principal Product Manager, Technical & Scientific Sales Support
Rose BioSolutions - Formerly the CDMO & Cell Solutions businesses of Charles River Laboratories